会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 62. 发明授权
    • Magnetic resonance imaging agents
    • 磁共振成像剂
    • US5384108A
    • 1995-01-24
    • US341978
    • 1989-04-24
    • Raghavan Rajagopalan
    • Raghavan Rajagopalan
    • A61K49/00A61K49/06C07C243/34C07D211/98C07D295/22
    • A61K49/06Y10S514/836
    • Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. The complexes are represented by the formula of: ##STR1## wherein A is --CHR.sup.2 --CHR.sup.3 -- or ##STR2## M.sup.+Z is a paramagnetic ion of an element with an atomic number of 21-29, 42-44 58-70, and a valence, Z, of +2 or +3; R.sup.1 groups may be the same or different and are selected from the group consisting of --O.sup.- and ##STR3## The R.sup.4, R.sup.5 and R.sup.6 groups are as defined in the disclosure. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.
    • 新型磁共振成像剂包括顺磁离子与聚氨基羧酸螯合剂的酰肼衍生物的复合物。 络合物由下式表示:其中A是-CHR 2 -CHR 3 - 或者M + Z是原子序数为21-29,42-44-58-70的元素的顺磁离子, 和+2或+3的化合价Z; R 1基团可以相同或不同,并且选自-O-和R 4,R 5和R 6基团如本公开中所定义。 这些新型成像剂的特征在于优异的NMR图像对比性质和生理溶液中的高溶解度。 执行NMR诊断程序的新方法包括向温血动物施用有效量的如上所述的复合物,然后将温血动物暴露于NMR成像过程,从而使至少一部分身体成像 温血动物。
    • 67. 发明授权
    • Tetrahydropyridyl derivatives
    • 四氢吡啶基衍生物
    • US4088653A
    • 1978-05-09
    • US716676
    • 1976-08-23
    • Edward E. KnausKinfe ReddaFrank W. Wandelmaier
    • Edward E. KnausKinfe ReddaFrank W. Wandelmaier
    • C07D211/98C07D213/89C07D311/72C07D401/12A61K31/44
    • C07D213/89C07D311/72Y10S514/866
    • Pharmaceutical compounds of the general formula ##STR1## and non-toxic pharmaceutically acceptable salts thereof, wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, lower alkyl having from 1 to 4 carbon atoms, lower alkoxy having from 1 to 4 carbon atoms and hydroxy lower alkyl having from 1 to 4 carbon atoms, and if R.sub.1 or R.sub.2 is other than hydrogen, the other substituent is hydrogen; and R.sub.3 is a member selected from the group consisting of pyridyl, phenyl, lower alkyl substituted pyridyl, lower alkoxy substituted pyridyl, lower alkyl substituted phenyl and lower alkoxy substituted phenyl, the lower alkyl and alkoxy substituents having from 1 to 4 carbon atoms. These compounds exhibit an analgesic, hyperglycemic or anti-inflammatory activity.
    • 通式为“IMAGE”的药物化合物及其无毒的药学上可接受的盐,其中R 1和R 2选自氢,具有1至4个碳原子的低级烷基,具有1至4个碳原子的低级烷氧基 和具有1至4个碳原子的羟基低级烷基,如果R1或R2不是氢,另一个取代基是氢; 并且R 3是选自吡啶基,苯基,低级烷基取代的吡啶基,低级烷氧基取代的吡啶基,低级烷基取代的苯基和低级烷氧基取代的苯基的成员,低级烷基和烷氧基取代基具有1至4个碳原子。 这些化合物表现出镇痛,高血糖或抗炎活性。